The company recently published new results on its MOBILE study, which found that CGM use increased time in range for people with Type 2 diabetes. New data shows people who stopped using a CGM saw time in range decrease.
Abbott received FDA clearance for an app to pair with its Freestyle Libre 2 glucose monitor. The app lets people get readings directly on their phone without using a reader.
In a wide-ranging interview, Dexcom’s CEO shared more about the company’s push to prove its continuous glucose monitor can be used both for patients with Type 1 and Type 2 diabetes, and how the device-maker is handling a growing number of competitors.
There is still health tech funding going on in late July? Wow! On Episode 138 of Health in 2 Point 00, Jess asks me about Ro getting $200M from General Catalyst to expand their Telehealth platform, Indigo Diabetes raising 38M Euros to develop its CGM Sensor, Angle Health landing $4M to create a health plan …